Ribozyme biotechnology: emerging opportunities for medical applications in the RNA therapeutics era

Mar 5, 2026Medical review (2021)

New uses of ribozyme technology for medical treatments with RNA-based drugs

AI simplified

mRNA Technology on OpenScience ↗PubMed ↗DOI ↗OA ↗

Abstract

Recent advancements have revitalized the potential of small self-cleaving ribozymes as RNA-based therapeutics.

Comparative genomics has identified new classes of ribozymes, such as Twister, Pistol, Hatchet, and Hovlinc.
High-resolution studies have clarified the structures and mechanisms of these ribozymes.
Chemical modifications and innovative delivery systems have enhanced the stability and effectiveness of ribozymes.
New applications, including ligand-responsive aptazymes and the StitchR RNA trans-ligation platform, demonstrate the versatility of catalytic RNA.
These developments suggest a redefined role for ribozymes in fields like oncology, virology, and genetic medicine.

AI simplified

RNA-based medicines have transformed modern therapeutics, exemplified by the clinical success of small interfering RNAs (siRNAs), antisense oligonucleotides (ASOs), and mRNA vaccines. Small self-cleaving ribozymes - compact catalytic RNA species capable of programmable cleavage and ligation - were among the earliest RNA drugs explored, yet their progress was initially hindered by instability, nuclease degradation, inefficient intracellular delivery, and immune activation. In this Perspective, we discuss how recent technological convergence has revived their potential. Comparative genomics has uncovered new catalytic classes, including Twister, Pistol, Hatchet, and Hovlinc ribozymes, thereby expanding the catalytic repertoire. High-resolution structural and computational studies have elucidated their reaction architectures, while chemical modifications and advanced nanocarrier systems - such as DNA nanostructures, spherical nucleic acids, and lipid nanoparticles - have markedly improved molecular stability and delivery efficiency. Emerging applications, from ligand-responsive aptazymes and ribozyme-SNA conjugates to the StitchR RNA trans-ligation platform, further illustrate the expanding biomedical versatility of catalytic RNA. Together, these advances are redefining the role of ribozymes in oncology, virology, and genetic medicine. No longer a dormant concept, ribozymes now stand as an evolving frontier - rationally engineered catalysts that continue to inspire technological creativity and renewed optimism in RNA therapeutics.

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View full text (XML) ↗View full text ↗

Ribozyme biotechnology: emerging opportunities for medical applications in the RNA therapeutics era

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the mrna technology brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the mrna technology brief